Health Canada needs to act on laboratory-developed diagnostics.
作者信息
Holloway Kelly, Miller Fiona A, Rousseau François, Gutierrez Alberto, Hogarth Stuart
机构信息
Institute of Health Policy, Management and Evaluation (Holloway, Miller), University of Toronto, Toronto, Ont.; Department of Molecular Biology, Medical Biochemistry and Pathology (Rousseau), Université Laval, Québec, Que.; NDA Partners, LLC (Gutierrez), Va.; Department of Sociology (Hogarth), University of Cambridge, Cambridge, UK.
Institute of Health Policy, Management and Evaluation (Holloway, Miller), University of Toronto, Toronto, Ont.; Department of Molecular Biology, Medical Biochemistry and Pathology (Rousseau), Université Laval, Québec, Que.; NDA Partners, LLC (Gutierrez), Va.; Department of Sociology (Hogarth), University of Cambridge, Cambridge, UK
出版信息
CMAJ. 2019 Sep 30;191(39):E1067-E1069. doi: 10.1503/cmaj.190550.
Abstract
摘要
相似文献
1
Health Canada needs to act on laboratory-developed diagnostics.加拿大卫生部需要对实验室研发的诊断方法采取行动。
CMAJ. 2019 Sep 30;191(39):E1067-E1069. doi: 10.1503/cmaj.190550.
2
Precision medicine: what's all the fuss about?精准医学：究竟在大惊小怪些什么？
Scand J Clin Lab Invest Suppl. 2016;245:S2-5. doi: 10.1080/00365513.2016.1206434. Epub 2016 Aug 17.
3
Regulatory approval pathways for molecular diagnostic technology.
Methods Mol Biol. 2012;823:409-20. doi: 10.1007/978-1-60327-216-2_27.
4
CDx, NGS and regulation: five perspectives from the Pistoia Alliance.CDx、NGS 和监管：Pistoia 联盟的五个视角。
Drug Discov Today. 2019 Nov;24(11):2120-2125. doi: 10.1016/j.drudis.2019.07.002. Epub 2019 Jul 12.
5
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
Nat Biotechnol. 2020 Mar;38(3):279-283. doi: 10.1038/s41587-020-0440-4.
6
Methylation-sensitive high-resolution melting in the context of legislative requirements for validation of analytical procedures for diagnostic applications.甲基化敏感高分辨率熔解在立法要求的背景下，用于验证诊断应用分析程序。
Expert Rev Mol Diagn. 2012 Jan;12(1):39-47. doi: 10.1586/erm.11.88.
7
Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.中美欧在肿瘤药物审批流程上的异同点——侧重于体外伴随诊断。
Clin Cancer Res. 2014 Mar 15;20(6):1445-52. doi: 10.1158/1078-0432.CCR-13-1761.
8
Testing in a Pandemic - Improving Access, Coordination, and Prioritization.疫情期间的检测——改善可及性、协调性和优先级
N Engl J Med. 2021 Jan 21;384(3):197-199. doi: 10.1056/NEJMp2025173. Epub 2021 Jan 16.
9
Turf war over diagnostic testing.
J Natl Compr Canc Netw. 2015 Apr;13(4):375. doi: 10.6004/jnccn.2015.0051.
10
Regulatory In Vitro Diagnostics Landscape in Africa: Update on Regional Activities.非洲监管体外诊断领域：区域活动最新情况。
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S135-40. doi: 10.1093/cid/civ553.
引用本文的文献
1
A comparative analysis of non-invasive prenatal testing in Ontario and Quebec: the role of governing style in health technology innovation & adoption.安大略省和魁北克省的非侵入性产前检测比较分析：治理风格在医疗技术创新和采用中的作用。
BMC Health Serv Res. 2023 Mar 9;23(1):231. doi: 10.1186/s12913-023-09245-6.
2
Regulation of Molecular Farming Products.分子农业产品的调控。
Methods Mol Biol. 2022;2480:313-333. doi: 10.1007/978-1-0716-2241-4_17.
3
Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).实验室自建检测方法：符合国际最新技术水平及欧盟法规（EU）2017/746（欧盟体外诊断医疗器械法规）的监管策略设计
Ther Innov Regul Sci. 2022 Jan;56(1):47-64. doi: 10.1007/s43441-021-00323-7. Epub 2021 Jul 21.
4
The Canadian Standards Association Technical Committee Z252.11 for Lab-developed Tests provides information.加拿大标准协会实验室自建检测技术委员会Z252.11提供了相关信息。
CMAJ. 2020 Oct 5;192(40):E1166-E1167. doi: 10.1503/cmaj.76509.
5
Responses to "Health Canada needs to act on laboratory-developed diagnostics".对“加拿大卫生部需对实验室研发诊断方法采取行动”的回应。
CMAJ. 2020 Mar 9;192(10):E261. doi: 10.1503/cmaj.74683.
6
Regulatory oversight for research tests and laboratory-developed diagnostics should be more nimble.对研究测试和实验室研发诊断方法的监管应该更加灵活。
CMAJ. 2019 Dec 16;191(50):E1388. doi: 10.1503/cmaj.73818.
本文引用的文献
1
Dangerous diagnostics? Regulatory reform in the genomic era.
BMJ. 2019 Feb 19;364:l640. doi: 10.1136/bmj.l640.
2
Accountability through regulation in Ontario's Medical Laboratory Sector.安大略省医学检验部门通过监管实现问责制。
Healthc Policy. 2014 Sep;10(Spec issue):67-78.
3
The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine.实验室医学在医疗保健中的作用：免疫分析的质量要求、标准化和前瞻性医学中的数据管理。
EPMA J. 2010 Dec;1(4):619-26. doi: 10.1007/s13167-010-0053-y. Epub 2010 Dec 2.
4
Laboratory quality regulations and accreditation standards in Canada.加拿大的实验室质量法规与认可标准。
Clin Biochem. 2009 Mar;42(4-5):249-55. doi: 10.1016/j.clinbiochem.2008.09.006.
Zotero 插件